Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 399

1.

Regulatory safety pharmacology evaluation of BIA 10-2474.

Hayes AW, Pressman P, Moser P, Soares-da-Silva P.

J Pharmacol Toxicol Methods. 2020 Jan 22;102:106677. doi: 10.1016/j.vascn.2020.106677. [Epub ahead of print]

2.

Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10-2474.

Bonifácio MJ, Sousa F, Aires C, Loureiro AI, Fernandes-Lopes C, Pires NM, Palma PN, Moser P, Soares-da-Silva P.

Br J Pharmacol. 2020 Jan 3. doi: 10.1111/bph.14973. [Epub ahead of print]

PMID:
31901141
3.

Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate.

Rogin J, Resnick T, Strom L, Ben-Menachem E, Kochen S, Blum D, Gama H, Soares-da-Silva P, Li Y, Grinnell T.

Acta Neurol Scand. 2020 Jan 1. doi: 10.1111/ane.13218. [Epub ahead of print]

PMID:
31894578
4.

Population Pharmacokinetic-Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS).

Araújo AM, Machado H, de Pinho PG, Soares-da-Silva P, Falcão A.

J Clin Pharmacol. 2019 Dec 3. doi: 10.1002/jcph.1560. [Epub ahead of print]

PMID:
31797395
5.

Bioelectrical impedance analysis of body composition for the anesthetic induction dose of propofol in older patients.

Araújo AM, Machado HS, Falcão AC, Soares-da-Silva P.

BMC Anesthesiol. 2019 Oct 11;19(1):180. doi: 10.1186/s12871-019-0856-x.

6.

Safety Profile of Opicapone in the Management of Parkinson's Disease.

Lees A, Ferreira JJ, Rocha JF, Rascol O, Poewe W, Gama H, Soares-da-Silva P.

J Parkinsons Dis. 2019;9(4):733-740. doi: 10.3233/JPD-191593.

PMID:
31498127
7.

Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.

Cabreira V, Soares-da-Silva P, Massano J.

Drugs. 2019 Apr;79(6):593-608. doi: 10.1007/s40265-019-01098-w. Review.

PMID:
30905034
8.

Acute salt loading induces sympathetic nervous system overdrive in mice lacking salt-inducible kinase 1 (SIK1).

Pires NM, Igreja B, Serrão MP, Matias EF, Moura E, António T, Campos FL, Brion L, Bertorello A, Soares-da-Silva P.

Hypertens Res. 2019 Aug;42(8):1114-1124. doi: 10.1038/s41440-019-0249-z. Epub 2019 Mar 20.

PMID:
30894696
9.

Effects of nepicastat upon dopamine-β-hydroxylase activity and dopamine and norepinephrine levels in the rat left ventricle, kidney, and adrenal gland.

Catelas DN, Serrão MP, Soares-Da-Silva P.

Clin Exp Hypertens. 2020;42(2):118-125. doi: 10.1080/10641963.2019.1583245. Epub 2019 Mar 1.

PMID:
30821508
10.

Repurposing nitrocatechols: 5-Nitro-α-cyanocarboxamide derivatives of caffeic acid and caffeic acid phenethyl ester effectively inhibit aggregation of tau-derived hexapeptide AcPHF6.

Silva T, Mohamed T, Shakeri A, Rao PPN, Soares da Silva P, Remião F, Borges F.

Eur J Med Chem. 2019 Apr 1;167:146-152. doi: 10.1016/j.ejmech.2019.02.006. Epub 2019 Feb 4.

PMID:
30771602
11.

Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors.

Pinheiro SD, Serrão MP, Silva T, Borges F, Soares-da-Silva P.

Eur J Pharmacol. 2019 Mar 15;847:53-60. doi: 10.1016/j.ejphar.2019.01.027. Epub 2019 Jan 24.

PMID:
30685433
12.

Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P.

Eur J Neurol. 2019 Jul;26(7):953-960. doi: 10.1111/ene.13914. Epub 2019 Mar 25.

13.

Effects of zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failure.

Igreja B, Pires NM, Wright LC, Soares-da-Silva P.

Eur J Pharmacol. 2019 Jan 5;842:125-132. doi: 10.1016/j.ejphar.2018.10.030. Epub 2018 Oct 26.

PMID:
30401628
14.

Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures.

Costa R, Steinhoff B, Gama H, Ikedo F, Rocha JF, Soares-da-Silva P.

Drugs Aging. 2018 Dec;35(12):1109-1117. doi: 10.1007/s40266-018-0602-y.

15.

Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.

Kitajima T, Mizote S, Bonifácio MJ, Umemura T, Yoneda K, Moser P, Soares-da-Silva P, Tanaka M.

Neuropharmacology. 2018 Dec;143:282-288. doi: 10.1016/j.neuropharm.2018.10.001. Epub 2018 Oct 2.

16.

Discovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 10-2474) of Fatty Acid Amide Hydrolase.

Kiss LE, Beliaev A, Ferreira HS, Rosa CP, Bonifácio MJ, Loureiro AI, Pires NM, Palma PN, Soares-da-Silva P.

ChemMedChem. 2018 Oct 22;13(20):2177-2188. doi: 10.1002/cmdc.201800393. Epub 2018 Sep 11.

17.

Effects of eslicarbazepine on slow inactivation processes of sodium channels in dentate gyrus granule cells.

Holtkamp D, Opitz T, Hebeisen S, Soares-da-Silva P, Beck H.

Epilepsia. 2018 Aug;59(8):1492-1506. doi: 10.1111/epi.14504. Epub 2018 Jun 28.

18.

Polyamine Modulation of Anticonvulsant Drug Response: A Potential Mechanism Contributing to Pharmacoresistance in Chronic Epilepsy.

Beckonert NM, Opitz T, Pitsch J, Soares da Silva P, Beck H.

J Neurosci. 2018 Jun 13;38(24):5596-5605. doi: 10.1523/JNEUROSCI.0640-18.2018. Epub 2018 May 22.

19.

Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate.

Gidal BE, Jacobson MP, Ben-Menachem E, Carreño M, Blum D, Soares-da-Silva P, Falcão A, Rocha F, Moreira J, Grinnell T, Ludwig E, Fiedler-Kelly J, Passarell J, Sunkaraneni S.

Acta Neurol Scand. 2018 Sep;138(3):203-211. doi: 10.1111/ane.12950. Epub 2018 May 6.

20.

Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.

Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B, Soares-da-Silva P.

Neurology. 2018 May 22;90(21):e1849-e1857. doi: 10.1212/WNL.0000000000005557. Epub 2018 Apr 25.

PMID:
29695590
21.

Eslicarbazepine acetate exposure in pregnant women with epilepsy.

Costa R, Magalhães LM, Graça J, Vieira M, Gama H, Moreira J, Rocha JF, Soares-da-Silva P.

Seizure. 2018 May;58:72-74. doi: 10.1016/j.seizure.2018.04.007. Epub 2018 Apr 10. Review.

22.

Antihypertensive effect of etamicastat in dopamine D2 receptor-deficient mice.

Armando I, Asico LD, Wang X, Jones JE, Serrão MP, Cuevas S, Grandy DK, Soares-da-Silva P, Jose PA.

Hypertens Res. 2018 Jul;41(7):489-498. doi: 10.1038/s41440-018-0041-5. Epub 2018 Apr 13.

23.
24.

Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures.

Jóźwiak S, Veggiotti P, Moreira J, Gama H, Rocha F, Soares-da-Silva P.

Epilepsy Behav. 2018 Apr;81:1-11. doi: 10.1016/j.yebeh.2018.01.029. Epub 2018 Feb 22.

25.

In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.

Bicker J, Alves G, Fortuna A, Soares-da-Silva P, Falcão A.

Eur J Pharm Sci. 2018 May 30;117:35-40. doi: 10.1016/j.ejps.2018.02.006. Epub 2018 Feb 8.

PMID:
29428540
26.

Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.

Trinka E, Ben-Menachem E, Kowacs PA, Elger C, Keller B, Löffler K, Rocha JF, Soares-da-Silva P.

Epilepsia. 2018 Feb;59(2):479-491. doi: 10.1111/epi.13993. Epub 2018 Jan 25.

27.

Reliability of body-weight scalars on the assessment of propofol induction dose in obese patients.

Araújo AM, Machado HS, Falcão AC, Soares-da-Silva P.

Acta Anaesthesiol Scand. 2018 Apr;62(4):464-473. doi: 10.1111/aas.13039. Epub 2017 Nov 21.

PMID:
29159892
28.

Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.

Krauss G, Biton V, Harvey JH, Elger C, Trinka E, Soares da Silva P, Gama H, Cheng H, Grinnell T, Blum D.

Epilepsy Res. 2018 Jan;139:1-8. doi: 10.1016/j.eplepsyres.2017.10.021. Epub 2017 Nov 4.

29.

Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.

Elger C, Koepp M, Trinka E, Villanueva V, Chaves J, Ben-Menachen E, Kowacs PA, Gil-Nagel A, Moreira J, Gama H, Rocha JF, Soares-da-Silva P.

CNS Neurosci Ther. 2017 Dec;23(12):961-972. doi: 10.1111/cns.12765. Epub 2017 Oct 13.

30.

Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors.

Bicker J, Fortuna A, Alves G, Soares-da-Silva P, Falcão A.

Drug Metab Dispos. 2017 Dec;45(12):1282-1291. doi: 10.1124/dmd.117.077883. Epub 2017 Sep 15.

PMID:
28916530
31.

The effect of PRR ligands on the membrane potential of intestinal epithelial cells.

Magalhães D, Soares-da-Silva P, Magro F.

Pharmacol Rep. 2017 Oct;69(5):978-984. doi: 10.1016/j.pharep.2017.04.010. Epub 2017 Apr 23.

PMID:
28837901
32.

Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience.

Gama H, Vieira M, Costa R, Graça J, Magalhães LM, Soares-da-Silva P.

Drug Saf. 2017 Dec;40(12):1231-1240. doi: 10.1007/s40264-017-0576-4. Review.

33.

A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat.

Gonçalves D, Alves G, Fortuna A, Bonifácio MJ, Soares-da-Silva P, Falcão A.

Neuropharmacology. 2017 Oct;125:146-155. doi: 10.1016/j.neuropharm.2017.07.019. Epub 2017 Jul 19.

PMID:
28734868
34.

Concerns Regarding Opicapone as Adjunct to Levodopa Therapy-Reply.

Lees AJ, Rocha JF, Soares-da-Silva P.

JAMA Neurol. 2017 Jul 1;74(7):873. doi: 10.1001/jamaneurol.2017.0726. No abstract available.

PMID:
28531266
35.

Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat.

Gonçalves D, Alves G, Fortuna A, Soares-da-Silva P, Falcão A.

Toxicol Appl Pharmacol. 2017 May 15;323:9-15. doi: 10.1016/j.taap.2017.03.013. Epub 2017 Mar 16.

PMID:
28322896
36.

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P; BIPARK-2 Study Investigators.

JAMA Neurol. 2017 Feb 1;74(2):197-206. doi: 10.1001/jamaneurol.2016.4703.

PMID:
28027332
37.

Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.

Rocha JF, Sicard É, Fauchoux N, Falcão A, Santos A, Loureiro AI, Pinto R, Bonifácio MJ, Nunes T, Almeida L, Soares-da-Silva P.

Br J Clin Pharmacol. 2017 Mar;83(3):540-553. doi: 10.1111/bcp.13156. Epub 2016 Dec 2.

38.

Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity.

Silva T, Mohamed T, Shakeri A, Rao PP, Martínez-González L, Pérez DI, Martínez A, Valente MJ, Garrido J, Uriarte E, Serrão P, Soares-da-Silva P, Remião F, Borges F.

J Med Chem. 2016 Aug 25;59(16):7584-97. doi: 10.1021/acs.jmedchem.6b00666. Epub 2016 Aug 5.

PMID:
27463695
39.

Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.

Rocha JF, Ferreira JJ, Falcão A, Santos A, Pinto R, Nunes T, Almeida L, Soares-da-Silva P.

Clin Pharmacol Drug Dev. 2016 May;5(3):232-40. doi: 10.1002/cpdd.217. Epub 2015 Oct 20.

PMID:
27163503
40.

Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects.

Falcão A, Rocha JF, Santos A, Nunes T, Soares-da-Silva P.

Clin Pharmacol Drug Dev. 2016 Mar;5(2):150-61. doi: 10.1002/cpdd.213. Epub 2015 Oct 16.

PMID:
27138028
41.

Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study.

Pinto R, l'Hostis P, Patat A, Homery MC, Falcão A, Nunes T, Rocha JF, Soares-da-Silva P.

Clin Pharmacol Drug Dev. 2015 Nov;4(6):454-62. doi: 10.1002/cpdd.188. Epub 2015 May 7.

PMID:
27137718
42.

A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates.

Bicker J, Alves G, Fortuna A, Soares-da-Silva P, Falcão A.

Int J Pharm. 2016 Mar 30;501(1-2):102-11. doi: 10.1016/j.ijpharm.2016.01.074. Epub 2016 Feb 1.

PMID:
26836708
43.

Sustained high blood pressure reduction with etamicastat, a peripheral selective dopamine β-hydroxylase inhibitor.

Igreja B, Wright LC, Soares-da-Silva P.

J Am Soc Hypertens. 2016 Mar;10(3):207-16. doi: 10.1016/j.jash.2015.12.011. Epub 2015 Dec 19.

PMID:
26803288
44.

Role of epithelial ion transports in inflammatory bowel disease.

Magalhães D, Cabral JM, Soares-da-Silva P, Magro F.

Am J Physiol Gastrointest Liver Physiol. 2016 Apr 1;310(7):G460-76. doi: 10.1152/ajpgi.00369.2015. Epub 2016 Jan 7. Review.

45.

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 investigators.

Lancet Neurol. 2016 Feb;15(2):154-165. doi: 10.1016/S1474-4422(15)00336-1. Epub 2015 Dec 23.

PMID:
26725544
46.

Amine neurotransmitters, inflammation and epithelial sodium transport.

Soares-da-Silva P, Cabral JM, Magalhães D, Fraga S, Magro F.

Exp Physiol. 2016 Apr;101(4):459-64. doi: 10.1113/EP085284. Epub 2015 Dec 14. Review.

47.

Carbamazepine aggravates absence seizures in two dedicated mouse models.

Pires NM, Bonifácio MJ, Soares-da-Silva P.

Pharmacol Rep. 2015 Oct;67(5):986-95. doi: 10.1016/j.pharep.2015.03.007. Epub 2015 Mar 23.

PMID:
26398395
48.

Short- and long-term regulation of intestinal Na+/H+ exchange by Toll-like receptors TLR4 and TLR5.

Cabral JM, Grácio D, Soares-da-Silva P, Magro F.

Am J Physiol Gastrointest Liver Physiol. 2015 Oct 15;309(8):G703-15. doi: 10.1152/ajpgi.00124.2015. Epub 2015 Aug 20.

49.

Development of a liquid chromatography assay for the determination of opicapone and BIA 9-1079 in rat matrices.

Gonçalves D, Alves G, Fortuna A, Soares-da-Silva P, Falcão A.

Biomed Chromatogr. 2016 Mar;30(3):312-22. doi: 10.1002/bmc.3550. Epub 2015 Aug 17.

PMID:
26147707
50.

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.

Soares-da-Silva P, Pires N, Bonifácio MJ, Loureiro AI, Palma N, Wright LC.

Pharmacol Res Perspect. 2015 Mar;3(2):e00124. doi: 10.1002/prp2.124. Epub 2015 Mar 30. Review.

Supplemental Content

Loading ...
Support Center